Volume 22, Number 3—March 2016
Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis
|500 Patients on BDQ by July 2015||1,258 patients by October 1, 2015|
|500 Patients on DLM by Jan 2016||>100 patients by October 1, 2015|
|TA given to 25 countries by 2016
||Ongoing, already provided in 21 countries
|BDQ and DLM routinely used by 20 countries by end of 2016||BDQ: 9 countries plus European Union by October 1, 2015; additional 20 by the mid-2016|
|DLM: 2 countries plus European Union by October 1, 2015; plans for other countries expected to be discussed in December 2015
|BDQ and DLM dossiers submitted for registration in 25 countries by beginning of 2016||BDQ: 26 countries by October 1, 2015|
|DLM: 3 countries by October 1 2015|
*BDQ, bedaquiline; DLM, delamanid.
Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.